Advertisement

 

 

Rapid Clinical and Radiographic Response With Combined Dabrafenib and Trametinib in Adults With BRAF-Mutated High-Grade Glioma.

Rapid Clinical and Radiographic Response With Combined Dabrafenib and Trametinib in Adults With BRAF-Mutated High-Grade Glioma.
Author Information (click to view)

Johanns TM, Ferguson CJ, Grierson PM, Dahiya S, Ansstas G,


Johanns TM, Ferguson CJ, Grierson PM, Dahiya S, Ansstas G, (click to view)

Johanns TM, Ferguson CJ, Grierson PM, Dahiya S, Ansstas G,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Journal of the National Comprehensive Cancer Network : JNCCN 16(1) 4-10 doi 10.6004/jnccn.2017.7032

Abstract

BRAF V600E mutations have been successfully treated with targeted therapy in melanoma, non-small cell lung cancer, and thyroid cancer. Interestingly, these mutations have also been identified in a subset of pediatric and adult brain tumors, with several cases reportedly responding to targeted therapy. However, these reports have been limited to single-agent BRAF inhibitor therapy and recurrent disease. Herein, we report dramatic clinical and radiographic responses to combination dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) in 2 adults with high-grade gliomas (HGGs), with 1 patient treated in the first-line setting. These observations, together with prior case reports, advocate for routine screening of BRAF point mutations in adult HGGs, and suggest that treatment with dual-targeted therapy, even in newly diagnosed cases, is safe and effective.

Submit a Comment

Your email address will not be published. Required fields are marked *

twelve + 16 =

[ HIDE/SHOW ]